Psoriasis Treatment Market Market Analysis

Over the past decade, the Asia‑Pacific psoriasis treatment landscape has transformed from fragmented symptom-focused care to a structured, long-term disease management framework, driven by rising clinical awareness and regulatory evolution. Japan has been at the forefront, with the Japanese Dermatological Association updating guidelines to incorporate biologic therapies and systemic assessments like the PASI score across tertiary centers such as Tokyo Medical University Hospital. In China, the National Clinical Research Center for Skin and Immune Diseases in Shanghai has documented a sharp increase in diagnosed moderate-to-severe cases, reflecting not just prevalence but improved access to hospital-based diagnostics. Australia has integrated psoriasis into chronic disease programs through Medicare-funded specialist consultations, allowing earlier escalation from topical to systemic therapies. South Korea’s major hospitals, including Seoul National University Hospital, routinely conduct biologic eligibility assessments, signaling a shift toward personalized, long-term care. In India, the Indian Association of Dermatologists Venereologists and Leprologists has strengthened dermatologist training and urban center outreach, improving detection and therapy initiation. Southeast Asian nations such as Thailand and Malaysia have increasingly established outpatient specialty clinics, reducing reliance on informal care. Collectively, these developments illustrate a recent history where the Asia-Pacific region has moved from episodic flare management toward continuous, data-informed disease control, underpinned by standardized severity assessment and expanding access to advanced therapies. According to the research report, "Asia-Pacific Psoriasis Treatment Market Research Report, 2031," published by Actual Market Research, the Asia-Pacific Psoriasis Treatment market is anticipated to grow at 10.68% CAGR from 2026 to 2031.Recent years have seen the Asia-Pacific psoriasis market shaped by regulatory reform, new therapy launches, and growing local innovation. In China, the National Health Security Administration added biologics such as risankizumab (Skyrizi) to the national reimbursement list, while domestic monoclonal antibody Jinlixi (Xeligekimab) received approval in 2024 for moderate-to-severe plaque psoriasis, signaling greater local participation in advanced therapies.

Biosimilars such as infliximab GB242 and adalimumab TQ-Z2301 are also being rolled out in provincial hospitals, expanding cost-effective treatment access. India marked a key milestone in 2025 when Sun Pharmaceutical Industries launched Ilumya (tildrakizumab), introducing a globally recognized IL-23 inhibitor to routine practice. Japan continues to lead in rapid regulatory approvals through the Pharmaceuticals and Medical Devices Agency, enabling timely adoption of emerging therapies. Australia and South Korea have integrated digital health platforms, teledermatology, and remote follow-up tools to improve adherence and monitor long-term outcomes. Clinical research hubs such as Peking Union Medical College Hospital and the National University Hospital of Singapore are conducting Phase II and III trials for novel agents including picankibart (IBI112), highlighting Asia-Pacific as a key contributor to global psoriasis evidence. These developments underscore a recent history of policy innovation, local and multinational therapy launches, biosimilar adoption, and digital integration, collectively shaping a region that now emphasizes sustained, evidence-driven psoriasis management. .

Market Dynamic

Psoriasis Treatment MarketSegmentation

Plaque Psoriasis is the largest by type in the Asia-Pacific Psoriasis Treatment Market due to its higher prevalence and impact on quality of life among patients.

Plaque psoriasis is the most common form of psoriasis, accounting for nearly 90% of all cases in the Asia-Pacific region. The condition is characterized by raised, red patches covered with silvery-white scales that appear primarily on the elbows, knees, scalp, and lower back. Its higher prevalence can be attributed to the fact that it manifests in both the young and elderly populations, affecting millions of people across diverse ethnic groups in countries like Japan, India, and China. The severity of plaque psoriasis often leads to significant physical discomfort and emotional distress, including intense itching, burning sensations, and an increased risk of comorbid conditions such as cardiovascular diseases and depression. As a result, patients with plaque psoriasis are more likely to seek medical treatment, driving the demand for various treatment options, including topicals, systemic therapies, and biologics. Additionally, the long-term nature of the disease necessitates continuous treatment, often escalating to biologic therapies as the disease progresses. As healthcare infrastructure and dermatology services improve, particularly in urban areas of countries such as South Korea and Singapore, there is an increasing capacity to manage moderate to severe plaque psoriasis effectively. Furthermore, initiatives to educate the public and healthcare professionals about psoriasis are helping to reduce the stigma associated with visible symptoms, encouraging more patients to seek timely treatment. Thus, plaque psoriasis dominates the treatment landscape as it significantly burdens the healthcare system, resulting in the most extensive market demand for therapies in the region.

Interleukin inhibitors are the fastest by drug class in the Asia-Pacific Psoriasis Treatment Market due to their targeted mechanism of action and superior efficacy in treating moderate-to-severe cases.

Interleukin inhibitors, particularly IL-23 and IL-17 inhibitors, have emerged as game-changers in the treatment of moderate-to-severe psoriasis, rapidly gaining traction in the Asia-Pacific region. These biologics target specific cytokines involved in the inflammatory pathways that drive psoriasis, making them more effective and with fewer side effects compared to traditional therapies. Drugs like secukinumab (Cosentyx) and guselkumab (Tremfya) have demonstrated significant efficacy in clinical trials, leading to faster clearance of psoriatic lesions and longer periods of remission. In countries such as Japan and Australia, these treatments are becoming the first line of defense for patients with more severe forms of psoriasis who have not responded well to conventional therapies like methotrexate or phototherapy. The rapid adoption of IL inhibitors can be attributed to their ability to offer sustained disease control with fewer hospital visits, thereby improving patient convenience and overall quality of life. Furthermore, the Asia-Pacific region is experiencing a surge in the availability of these biologics as pharmaceutical companies expand their market access, with local production facilities and increased regulatory approvals supporting widespread distribution. As treatment paradigms shift towards precision medicine, the demand for IL inhibitors is expected to grow, especially as more data on their long-term safety and efficacy become available. The fast uptake of IL inhibitors is also reflective of the broader trend toward biologic-based treatments in the region, driven by increasing awareness, better diagnostic capabilities, and improving healthcare infrastructure.

Biologics drugs are the largest by treatment type in the Asia-Pacific Psoriasis Treatment Market due to their efficacy in treating moderate-to-severe cases of psoriasis.

Biologic drugs have become the cornerstone for managing moderate-to-severe psoriasis in the Asia-Pacific region, especially due to their proven effectiveness in controlling inflammation and promoting long-term disease remission. These therapies, including TNF inhibitors like adalimumab (Humira) and newer agents such as IL-17 and IL-23 inhibitors, offer substantial improvements in both the clinical outcome and quality of life for patients. In countries like Japan, South Korea, and Australia, biologics are becoming the treatment of choice for patients who have not responded to traditional systemic treatments, such as methotrexate or cyclosporine. The increased adoption of biologics can be linked to the growing awareness among healthcare professionals about the potential of these therapies to provide better disease management with fewer side effects and complications. Additionally, the rising availability of biologics, supported by expanded national health insurance coverage and public reimbursement programs in countries like Japan, has made these treatments more accessible to patients, thereby driving their demand. With rapid advancements in pharmaceutical research and continuous clinical trials, biologics have evolved from being a last-resort treatment option to a preferred first-line therapy for many patients in Asia-Pacific. This shift is particularly evident in markets such as Australia, where healthcare policies have been adjusted to include biologics under government-funded healthcare systems like Medicare. Overall, biologics continue to dominate the treatment landscape, offering hope for improved disease control and better patient outcomes.

Oral is the fastest by mode of administration in the Asia-Pacific Psoriasis Treatment Market due to its convenience and growing patient preference for non-injection options.

Oral treatments for psoriasis have gained significant traction in the Asia-Pacific region due to their convenience and patient preference for non-injection-based therapies. Oral therapies, such as apremilast (Otezla), which target specific molecular pathways involved in the inflammatory process, have shown promise in treating moderate-to-severe psoriasis. These therapies are highly sought after by patients due to their ease of use, as they do not require frequent hospital visits or injections, which can be a barrier for many, especially in rural and remote areas. As healthcare systems across Asia, including countries like India and Southeast Asia, face challenges related to access and infrastructure, oral medications are seen as an easier, more accessible option for both patients and healthcare providers. The patient convenience factor is particularly important for managing chronic conditions like psoriasis, where long-term treatment adherence is key to disease control. Additionally, the introduction of oral systemic treatments has provided more options for patients who may have been reluctant to use biologics due to concerns about injections or the perceived complexity of biologic regimens. The ease of oral medication administration, combined with its relatively lower cost compared to biologics, has made oral therapies an appealing choice for a growing number of psoriasis patients. Moreover, the increasing approval of oral therapies in various Asia-Pacific markets, coupled with better awareness of their benefits, has led to a surge in their adoption, making them the fastest-growing mode of treatment.

Retail pharmacies are the largest by distribution channel in the Asia-Pacific Psoriasis Treatment Market due to their widespread accessibility and patient convenience.

Retail pharmacies dominate the psoriasis treatment distribution landscape in the Asia-Pacific region, primarily because of their widespread accessibility and ability to provide patients with over-the-counter (OTC) and prescription medications. In countries like India, Indonesia, and Malaysia, where healthcare infrastructure may be less developed in rural areas, retail pharmacies play a crucial role in ensuring access to essential psoriasis medications, including topical treatments like corticosteroids and vitamin D analogs. Retail pharmacies also provide an important channel for patients to access over-the-counter treatments, which is especially important in regions where healthcare costs may be prohibitive for a large portion of the population. In urban centers of countries like Japan and South Korea, retail pharmacies also serve as a critical point of contact for patients seeking both prescription and OTC products, with many pharmacies now offering consultations and guidance for managing psoriasis. As psoriasis management continues to evolve in Asia-Pacific, with more advanced therapies such as biologics becoming available, retail pharmacies are increasingly seen as integral to the distribution of these treatments, offering convenience and affordability. Retail pharmacies provide patients with an easily accessible, one-stop-shop experience for managing psoriasis, improving treatment adherence by simplifying the process of obtaining necessary medications. This ease of access is expected to keep retail pharmacies as the leading distribution channel in the region, even as new treatment options emerge.

Psoriasis Treatment Market Market Regional Insights

China is a leading region in the Asia-Pacific Psoriasis Treatment Market due to its rapidly expanding healthcare infrastructure and increasing adoption of biologic therapies.

China's psoriasis treatment market is quickly emerging as a dominant force in the Asia-Pacific region, driven by the country's rapidly evolving healthcare infrastructure and the growing adoption of biologics in dermatology. Over the past decade, China has made significant strides in improving its healthcare system, with government initiatives aimed at enhancing access to specialty care and advanced therapies. This has been further supported by the increasing availability of biologic treatments, such as secukinumab (Cosentyx) and guselkumab (Tremfya), which are now included in the National Reimbursement Drug List. This inclusion ensures that patients in China have broader access to high-cost biologics, a game-changer for those with moderate-to-severe psoriasis who were previously limited to traditional treatments. Hospitals in major cities like Beijing and Shanghai are now equipped with cutting-edge dermatology units that offer advanced diagnostic tools and targeted therapies, contributing to better disease management and patient outcomes. In addition, China’s growing middle class and rising health awareness have fueled the demand for effective and convenient treatments, especially biologics, which are increasingly seen as a long-term solution for psoriasis. The country’s regulatory bodies, including the National Medical Products Administration (NMPA), have also streamlined the approval process for new treatments, ensuring quicker market access for global and local drug manufacturers. Furthermore, China’s clinical research landscape is thriving, with numerous ongoing trials evaluating the safety and efficacy of novel psoriasis therapies.